NCT05775094

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with multiple myeloma (MM).

Conditions

• Osteoporosis
• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Romosozumab	Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).

Timeline

• Start date: 2023-03-07
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2023-03-20
• Last updated: 2025-12-19

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study